Unicycive Therapeutics, Inc. (UNCY)
USD 0.66
(-5.93%)
USD 0.66
(-5.93%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -18.28 Million | -15.65 Million | -5.76 Million | -1.45 Million | -1.17 Million | -775 Thousand |
| Net Income | -30.54 Million | -18.05 Million | -10.01 Million | -2.26 Million | -2.16 Million | -1.12 Million |
| Depreciation & Amortization | 284 Thousand | 161 Thousand | 13 Thousand | - | - | - |
| Deferred income taxes | -1.27 Million | - | 127 Thousand | - | - | - |
| Stock-based compensation | 1.76 Million | 1.04 Million | 966 Thousand | 232 Thousand | 24 Thousand | - |
| Change in working capital | -93 Thousand | 1.17 Million | -105 Thousand | -166 Thousand | 305 Thousand | 6000.00 |
| Other non-cash items | 11.57 Million | 21 Thousand | 3.24 Million | 739 Thousand | 660 Thousand | 308 Thousand |
| Investing Cash Flow | -12 Thousand | -2000.00 | -29 Thousand | - | - | - |
| Investments in PPE | -12 Thousand | -2000.00 | -29 Thousand | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 27.54 Million | -471 Thousand | 22.37 Million | 1.44 Million | 1.16 Million | 800 Thousand |
| Debt repayment | - | - | -15 Thousand | -160 Thousand | -9000.00 | -550 Thousand |
| Dividends payments | -867 Thousand | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 28.03 Million | 11 Thousand | 22.39 Million | 141 Thousand | 1.16 Million | 250 Thousand |
| Other Financing Activities | 27.54 Million | -482 Thousand | 22.37 Million | 1.46 Million | 9000.00 | 800 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 1.27 Million | 1.26 Million | 1.24 Million | -68 Thousand | 308 Thousand | 31 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -1.36 Million | -89 Thousand | -1.34 Million | -98 Thousand | -3000.00 | -25 Thousand |
| Cash at beginning of period | 455 Thousand | 16.57 Million | - | 15 Thousand | 25 Thousand | - |
| Cash at end of period | 9.7 Million | 455 Thousand | 16.57 Million | - | 15 Thousand | 25 Thousand |
| Capital Expenditure | -12 Thousand | -2000.00 | -29 Thousand | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 9.24 Million | -16.12 Million | 16.57 Million | -15 Thousand | -10 Thousand | 25 Thousand |
| Free Cash Flow | -18.29 Million | -15.65 Million | -5.79 Million | -1.45 Million | -1.17 Million | -775 Thousand |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 3.93 Million | -20.96 Million | -30.54 Million | -7.79 Million | -4.33 Million | -3.83 Million |
| Depreciation & Amortization | -113 Thousand | 284 Thousand | 284 Thousand | 82 Thousand | 79 Thousand | 78 Thousand |
| Deferred income taxes | - | - | -1.27 Million | -287 Thousand | - | - |
| Stock-based compensation | 641 Thousand | 522 Thousand | 1.76 Million | 550 Thousand | 929 Thousand | 144 Thousand |
| Change in working capital | 108 Thousand | 1.89 Million | -93 Thousand | 1.12 Million | 299 Thousand | -1.6 Million |
| Other non-cash items | -9.98 Million | 12.07 Million | 11.57 Million | 1.89 Million | -1.39 Million | -282 Thousand |
| Investing Cash Flow | -20 Thousand | -6000.00 | -12 Thousand | - | - | -12 Thousand |
| Investments in PPE | -20 Thousand | -6000.00 | -12 Thousand | - | - | -12 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -811 Thousand | 45.69 Million | 27.54 Million | -205 Thousand | -51 Thousand | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | -1.09 Million | -208 Thousand | -867 Thousand | -867 Thousand | - | - |
| Common Stock Repurchased | 13.08 Billion | - | - | -11.65 Billion | 10.32 Billion | - |
| Common Stock Issuance | - | 46.18 Million | 28.03 Million | 32.34 Million | - | - |
| Other Financing Activities | 284 Thousand | -496 Thousand | 27.54 Million | -205 Thousand | -51 Thousand | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -372 Thousand | 822 Thousand | 1.27 Million | 427 Thousand | 1.48 Million | -442 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 480 Thousand | 1.07 Million | -1.36 Million | 694 Thousand | -1.18 Million | -1.16 Million |
| Cash at beginning of period | 48.93 Million | 9.7 Million | 455 Thousand | 14.34 Million | 18.81 Million | 24.33 Million |
| Cash at end of period | 41.78 Million | 48.93 Million | 9.7 Million | 9.7 Million | 14.34 Million | 18.81 Million |
| Capital Expenditure | -20 Thousand | -6000.00 | -12 Thousand | - | - | -12 Thousand |
| Effect of forex changes on cash | - | - | - | -5.51 Million | - | 5.51 Million |
| Net cash flow / Change in cash | -7.15 Million | 39.22 Million | 9.24 Million | -4.64 Million | -4.47 Million | -5.51 Million |
| Free Cash Flow | -6.33 Million | -6.46 Million | -18.29 Million | -4.43 Million | -4.42 Million | -5.51 Million |
KANCHI
BML
605333
300011
0188
NDA